Publications by authors named "J L Ch'ng"

Viral infection leads to heterogeneous cellular outcomes ranging from refractory to abortive and fully productive states. Single cell transcriptomics enables a high resolution view of these distinct post-infection states. Here, we have interrogated the host-pathogen dynamics following reactivation of Epstein-Barr virus (EBV).

View Article and Find Full Text PDF

Viral infection leads to heterogeneous cellular outcomes ranging from refractory to abortive and fully productive states. Single cell transcriptomics enables a high resolution view of these distinct post-infection states. Here, we have interrogated the host-pathogen dynamics following reactivation of Epstein-Barr virus (EBV).

View Article and Find Full Text PDF

Spontaneous aortic thrombosis is exceedingly rare, and optimal treatment remains uncertain. We present an unusual case of a spontaneous aortic thrombus at the renal artery level in a patient undergoing active cisplatin treatment for urothelial carcinoma. Management included catheter-directed thrombolysis followed by thrombectomy.

View Article and Find Full Text PDF

is an opportunistic pathogen that is frequently co-isolated with other microbes in wound infections. While can subvert the host immune response and promote the survival of other microbes via interbacterial synergy, little is known about the impact of -mediated immune suppression on co-infecting microbes. We hypothesized that can attenuate neutrophil-mediated responses in mixed-species infection to promote survival of the co-infecting species.

View Article and Find Full Text PDF
Article Synopsis
  • Sargramostim (rhu GM-CSF) is used to enhance immune responses and help recover from chemotherapy-induced neutropenia, but its effectiveness against invasive fungal diseases (IFDs) is not well studied.
  • A review of 15 pediatric patients with malignancies and IFDs treated with sargramostim showed a high response rate, with 92% of evaluable patients responding positively to treatment.
  • The literature review, including 50 cases, also indicated a strong response rate of 82%, suggesting sargramostim could serve as a promising adjunctive therapy for patients with hematological cancers and difficult-to-treat IFDs.*
View Article and Find Full Text PDF